Decoding Hormones for Better Health Outcomes

Decoding Hormones: A Modern Guide to Cancer Prevention, Heart Health, and Longevity

Abstract

This comprehensive educational post aims to dispel the complexities and common misconceptions surrounding hormone therapy, guiding you through the latest evidence-based research from leading experts. From my perspective as a practitioner with a diverse background in integrative care, we will deconstruct pivotal studies, such as the Women’s Health Initiative (WHI), and explore the profound impact of hormones like estrogen, progesterone, and testosterone on nearly every aspect of health—from mood and cognition to heart, bone, and sexual wellness. We will dismantle long-standing myths, particularly those linking testosterone to prostate cancer and cardiovascular disease, and introduce critical concepts like the prostate saturation model and the receptor model of cancer. This journey will highlight the crucial differences between synthetic progestins and bioidentical progesterone, as well as between oral and non-oral hormone delivery. Furthermore, I will explain how integrative chiropractic care complements this functional medicine approach by addressing the body’s structural and neurological integrity, creating a holistic framework for preventing chronic disease and optimizing patient health. My goal is to empower you with a clear, scientifically grounded understanding of why personalized, evidence-based hormone optimization is essential for vitality and longevity.

Unraveling the Controversy: Why We Need to Rethink Hormone Therapy

Welcome. There’s a reason you’ve sought out this information. In the conventional healthcare landscape we navigate daily, many people find that the standard solutions are not working. They don’t feel better, and they aren’t thriving. As a clinician, my practice is built on asking “why”—a question that is too often discouraged in traditional medical training, where the answer is frequently, “That’s the way we’ve always done it.” This is not a sufficient answer when it comes to your health. We must understand the physiological basis for our treatments.

Let’s begin by questioning one of the most influential studies in modern medicine: the Women’s Health Initiative (WHI). What if the WHI, back in 2002, had used a different form of estrogen? Instead of the oral, conjugated equine estrogen (Premarin), what if they had used a 17-beta estradiol patch? This is a crucial distinction.

• Oral vs. Non-Oral Delivery: When you take a hormone in a pill form—the cheapest and easiest method for pharmaceutical mass production—it goes through your gastrointestinal tract and is processed by the liver in what is known as the first-pass metabolism. This process fundamentally alters the hormone’s effects. Your liver, working hard to metabolize the oral estrogen, is stimulated to produce other substances, including an excess of clotting factors. This is why oral contraceptives and drugs like Premarin increase the risk of blood clots.
• The Cardioprotective Dilemma: We know that estrogen has significant cardioprotective benefits. However, when administered orally, the increased production of clotting factors negates this benefit. Since most heart attacks and strokes involve a clotting event, the oral delivery system inadvertently created a new risk that overshadowed the hormone’s natural protective qualities. This led to the flawed conclusion that estrogen wasn’t helpful for cardiovascular health.

The problem was twofold: the wrong molecule (conjugated equine estrogens, which are not identical to human estrogen) and the wrong delivery system (oral). Had the study used bioidentical 17-beta estradiol, which fits perfectly into our body’s estrogen receptors, and a non-oral delivery system, such as a patch, to bypass the liver’s first-pass metabolism, the complications seen in the WHI—such as the increased risk of blood clots—would have been virtually eliminated.

The Progesterone vs. Progestin Debate: A Critical Distinction for Safety

The WHI didn’t just use the wrong estrogen; it used a synthetic progestin, medroxyprogesterone acetate (MPA), not natural progesterone. Has bioidentical progesterone, on its own, ever been shown to increase the risk of breast cancer in any credible study? No, not once. The trend toward increased breast cancer risk seen in the WHI was in the Prempro arm—the combination of Premarin and MPA.

If the correct molecules (17-beta estradiol and bioidentical progesterone) and the correct delivery system (non-oral) had been used, we wouldn’t be having this conversation today. Major medical organizations would likely be recommending that every woman begin bioidentical hormone therapy at the onset of menopause and continue it for life to maintain her health. This raises a fundamental biological question. If these hormones were inherently dangerous, why would our bodies produce them in high quantities, especially during pregnancy? Our physiology lacks mechanisms for intentionally creating toxic chemicals. The idea that our own natural hormones are harmful makes absolutely no sense from a biological standpoint.

I was in practice in 2002 when the results of the WHI were published in the Journal of the American Medical Association (JAMA) and splashed across the front page of Time magazine. Fear sells. The article, titled “The Truth About Hormones,” incited panic. My office had to hire an additional staff member just to handle the flood of calls from terrified patients demanding to stop their hormone therapy. The fallout was catastrophic. In 2002, about half of the women in the United States on hormone therapy stopped. Think about the consequences that have unfolded over the last 24 years, such as increased rates of cognitive decline, heart disease, and osteoporosis-related fractures.

Vindication Through Long-Term Data: What We Know Now

Science, when pursued honestly, eventually corrects itself. A follow-up report published in 2013, with a median follow-up of 18 years, stated, “Estrogen use was not associated with increased all-cause, cardiovascular, or cancer mortality” (Manson et al., 2013). This finding was a complete reversal of the initial panic, but it received little public attention. It was effectively the scientific community saying, “Never mind” to the millions of women who suffered as a result of the initial flawed interpretation.

The story gets even more compelling. A 2020 study published in JAMA continued to follow these women and found something extraordinary. The women who were in the estrogen-only treatment arm for approximately eight years had a lower incidence of breast cancer over the course of their lives and were less likely to die from breast cancer (Chlebowski et al., 2020). Let that sink in. This means that the only medicine in the history of medicine shown to reduce the chance of both getting breast cancer and dying from breast cancer in a prospective, randomized, placebo-controlled, long-term trial is estrogen. And this was demonstrated with Premarin—a formulation containing mostly horse estrogens! Imagine the protective power of bioidentical human estrogen. This data, published six years ago, should have revolutionized our approach.

The Science of Progesterone and the Menstrual Cycle

Understanding progesterone is key. First, we must get our terms straight. Progestins are not progesterone. When I read a study claiming “hormone replacement therapy (HRT) caused a 30% rise in dementia,” I know without looking that they are talking about a synthetic progestin like the one in Prempro. I immediately check the abstract to see two things: what the molecule is and what the delivery system is. This explains nearly everything. Synthetic progestins, such as medroxyprogesterone acetate, have a different molecular structure from our body’s own P4 (progesterone). They do not bind to our receptors in the same way and can have vastly different, often harmful, effects.

To understand progesterone’s role, let’s look at the normal menstrual cycle:

1. Follicular Phase: The cycle begins with low estrogen and progesterone. Rising estrogen causes the uterine lining (endometrium) to thicken and grow. This is a growth (proliferative) phase.
2. Ovulation: Around mid-cycle, an egg is released.
3. Luteal Phase: After ovulation, the corpus luteum produces high levels of progesterone. Progesterone’s job is to stabilize the endometrium. It stops the estrogen-driven growth and matures the lining.
4. Menstruation: If implantation does not occur, the drop in progesterone triggers an organized shedding of the uterine lining.

It’s a mistake to say progesterone “counteracts” estrogen. As Dr. Felice Gersh notes, they are synergistic—they work together. You can never accurately assess a hormone’s effect in a vacuum because that is not how our biology works.

The Hierarchy of Hormonal Influence: Mapping the Receptors

If we want to understand the relative importance of different hormones, we can look at the distribution of their receptors. This is fundamental physiology.

• Progesterone: Its receptors are concentrated in the brain, heart, bones, breasts, and genitourinary system. In every one of these locations, progesterone’s effect is positive and protective.
• Estrogen: This hormone expands its reach. You’ll find estrogen receptors in all the same places as progesterone, plus additional body systems.
• Testosterone: Here we see a major leap. Over 90% of the cells in the human body, whether male or female, have testosterone receptors. This alone should tell us how systemically crucial this hormone is for both sexes.
• Thyroid Hormone: At the top of the hierarchy sits thyroid hormone. An astonishing 99% of your cells express thyroid receptors, underscoring the thyroid’s role as a master regulator.

Given this, my philosophy is straightforward: correct all deficiencies. We experience a gradual decline in our hormones, and this loss contributes significantly to the aging process and the onset of chronic disease.

Debunking the Testosterone and Prostate Cancer Myth

For decades, a pervasive fear has linked testosterone therapy to prostate cancer. The world’s leading authority on this subject, Dr. Abraham Morgentaler of Harvard, discovered that this entire belief stemmed from a single, 100-year-old study with a grand total of two patients. Dr. Morgentaler systematically dismantled this myth with rigorous research:

• Do men with high testosterone have more prostate cancer? No.
• Do men with low testosterone have less prostate cancer? No.

In fact, his work has shown the opposite. Low testosterone is now recognized as an independent risk factor for developing prostate cancer. This brings us to a crucial concept: the prostate saturation model. Dr. Morgentaler’s research found that, on average, the prostate’s androgen receptors are fully saturated at a total testosterone level of about 200 ng/dL (Morgentaler & Traish, 2009).

This means if a patient’s testosterone is 350 ng/dL, his prostate receptors are already “full.” Raising his systemic level to 950 ng/dL exposes his prostate to zero additional testosterone stimulation. Therefore, optimizing his level cannot logically make BPH worse or cause PSA to rise. If a patient’s PSA does increase after starting testosterone therapy, it is a red flag that an underlying, previously undetected prostate cancer may be present. The testosterone did not cause the cancer; it unmasked it.

Redefining “Normal”: The Critical Shift to “Optimal”

A typical lab report for male testosterone might show a reference range of 300 to 1100 ng/dL. A patient with a level of 325 is told, “You’re normal.” But what does this range represent? It is a reference range, a statistical bell curve. The bottom number is the 2.5th percentile, and the top is the 97.5th percentile. A level of 325 means you are in the bottom few percentiles. There is no such thing as “low normal.” There is only suboptimal and optimal.

Groundbreaking research on cognitive health illustrates this. A study of 160,000 men revealed that men with testosterone levels in the lowest quintile (the bottom 20%) had a 48% to 80% higher risk of developing dementia compared to men in the highest quintile (Yeap et al., 2021). My clinical goal is to bring my male patients into the upper quartile of the reference range for young, healthy adult males. This isn’t about creating superhuman levels; it’s about restoring a more favorable physiological state.

The Heart of the Matter: Testosterone and Cardiovascular Protection

Much of the fear surrounding testosterone and heart health stems from a widely publicized but profoundly flawed VA study (Vigen et al., 2013). The study’s raw data showed that the group that received a testosterone prescription had fewer heart attacks than the untreated group. The scary headline was generated by a fabricated predictive model.

The truth, supported by a wealth of credible research, is that low testosterone is an independent risk factor for cardiovascular disease, and optimizing it is profoundly protective. Work by researchers like Traish has shown that testosterone is vital for the health of the endothelium, the lining of our arteries (Traish, 2014). It reduces inflammation, improves vasodilation, enhances insulin sensitivity, and improves body composition. A study looking at coronary artery blockage found a direct inverse relationship: the lower a man’s testosterone, the more severe his blockages (Yildiz et al., 2021). Testosterone is not detrimental to the heart; rather, it serves as one of its most significant allies.

A New Paradigm for Cancer: Hormones as Guardians

Let’s venture into cancer, guided by the receptor model. This model explains how hormones interact with receptors on our cells and how that interaction can either promote or prevent cancer. Our bodies are constantly clearing out old, damaged cells through apoptosis, or programmed cell death. Certain proteins, like BCL-2, act as anti-apoptotic regulators. Too much BCL-2 allows a cell to evade death signals and become cancerous. Another critical player is the p53 protein, the “guardian of the genome,” which acts as a tumor suppressor.

This brings us to the groundbreaking work of Dr. Rebecca Glaser, a breast cancer surgeon. Her work demonstrates that testosterone is fundamentally anti-proliferative and anti-inflammatory in breast tissue (Glaser & Dimitrakakis, 2013). One of her pivotal studies addressed women on aromatase inhibitors for breast cancer, which block estrogen production but have debilitating side effects. Dr. Glaser showed that giving these women testosterone along with their anti-estrogen therapy allowed them to stay on their life-saving treatment by preserving their muscle mass, bone density, and quality of life.

In a large prospective trial, Dr. Glaser’s predictive model anticipated 80 cases of invasive breast cancer in a cohort of women. In the group receiving testosterone therapy, there were only 11 cases—a 39% reduction in the incidence of breast cancer. This is preventative medicine at its best.

A Symptom-Based Approach to Diagnosis and Treatment

The current guidelines for diagnosing low testosterone are fundamentally flawed. They rely on arbitrary numerical cutoffs that fail to account for individual physiology, particularly the impact of Sex Hormone-Binding Globulin (SHBG), the protein that binds to testosterone, making it inactive. A patient’s journey often looks like this:

• The 20-Year-Old: A young woman with robust total testosterone and low SHBG, resulting in high levels of “free” or bioavailable testosterone, fueling her vitality.
• The 35-Year-Old: Fifteen years later, after children and life stress, her total testosterone has likely decreased by 50%. Factors like aging and oral medications have caused her SHBG to skyrocket. The result is a catastrophic drop in free testosterone, leading to fatigue, pain, anxiety, and low libido. This is the patient I see every week, told her labs are “normal” yet left without a diagnosis.

The international consensus is moving toward a new paradigm: treat the patient, not the number. Diagnosis should be guided by symptoms. The cause of the deficiency is secondary to the safe restoration of balance. And there is no age limit for therapy.

Integrative Chiropractic Care: A Foundational Partner in Hormonal Health

As a Doctor of Chiropractic, I see the body as an interconnected system. Hormonal balance doesn’t happen in a vacuum; it is deeply intertwined with our neurological and structural health. This is where integrative chiropractic care becomes a crucial component of a holistic treatment plan.

1. Neuro-Endocrine Axis: The nervous system, particularly the hypothalamus and pituitary gland, is the master controller of the endocrine system. Spinal misalignments, or subluxations, can create nerve interference that disrupts signaling between the brain and hormone-producing glands. By performing precise chiropractic adjustments, we can restore proper nerve function, helping to normalize this communication pathway.
2. Stress and the Adrenal Glands: Chronic physical and emotional stress places a heavy burden on the adrenal glands, leading to cortisol dysregulation. This “adrenal fatigue” can disrupt the entire hormonal cascade. Chiropractic care has been shown to reduce the body’s stress response by downregulating the sympathetic (fight-or-flight) nervous system, helping preserve adrenal function and create a more stable hormonal environment.
3. Structural Support and Pain Reduction: The musculoskeletal pain that often accompanies hormonal shifts (such as joint pain during menopause) can be effectively managed with chiropractic care. By improving joint mobility, correcting posture, and reducing mechanical stress, we decrease the body’s overall inflammatory load, which is itself a stressor that negatively impacts hormonal balance.
4. A Synergistic Approach: When a patient presents with chronic pain and fatigue, hallmarks of testosterone deficiency, a purely structural approach is incomplete. By combining hormone optimization with targeted integrative chiropractic care, we address both the biochemical and biomechanical drivers of a patient’s symptoms. This synergy accelerates recovery and empowers patients not just to manage their condition but to truly thrive.

My approach is to use precise, data-driven hormone optimization as a primary tool, supported by nutritional science, lifestyle coaching, and chiropractic care, to ensure the body’s foundational systems function optimally. This synergistic strategy allows us to go beyond just managing disease and truly cultivate a state of vibrant, resilient health.

References

Click to expand

Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., Manson, J. E., Stefanick, M. L., Pan, K., … & Prentice, R. L. (2020). Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA, 324(4), 369–380. doi.org/10.1001/jama.2020.9482

Garg, G., Ruan, X., & Mueck, A. O. (2022). Estradiol/micronized progesterone as hormone therapy for postmenopausal women: A narrative review of evidence. Gynecological Endocrinology, 38(9), 705–712. doi.org/10.1080/09513590.2022.2104529

Glaser, R., & Dimitrakakis, C. (2013). Testosterone therapy in women: Myths and misconceptions. Maturitas, 74(3), 230–239. doi.org/10.1016/j.maturitas.2013.01.003

Green, J. R. (2013). The effects of pellet hormone therapy on bone density. Obstetrics & Gynecology, 121, 90S. doi.org/10.1097/01.AOG.0000428669.97017.38

Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., … & Wactawski-Wende, J. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA, 310(13), 1353–1368. doi.org/10.1001/jama.2013.278040

Morgentaler, A., Miner, M. M., Caliber, M., Guay, A. T., Khera, M., & Traish, A. M. (2015). Testosterone therapy and cardiovascular risk: Advances and controversies. Mayo Clinic Proceedings, 90(2), 224–251. doi.org/10.1016/j.mayocp.2014.10.011

Morgentaler, A., & Traish, A. M. (2009). Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. European Urology, 55(2), 310-320. doi.org/10.1016/j.eururo.2008.09.024

Rizk, P. J., Kedia, S., Kohn, T. P., & Pastuszak, A. W. (2021). Testosterone and opioid-induced androgen deficiency. Translational Andrology and Urology, 10(3), 1451–1464. doi.org/10.21037/tau-20-854

Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., … & Writing Group for the Women’s Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA, 288(3), 321–333. doi.org/10.1001/jama.288.3.321

Singh, M., & Su, C. (2013). Progesterone and neuroprotection. Hormones and Behavior, 63(2), 284–290. doi.org/10.1016/j.yhbeh.2012.07.009

Traish, A. M. (2014). Testosterone and cardiovascular disease: an old idea with modern clinical implications. Current Opinion in Endocrinology, Diabetes and Obesity, 21(4), 304–314. doi.org/10.1097/MED.0000000000000078

Vigen, R., O’Donnell, C. I., Barón, A. E., Grunwald, G. K., Maddox, T. M., Bradley, S. M., … & Ho, P. M. (2013). Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA, 310(17), 1829–1836. doi.org/10.1001/jama.2013.280386

Yeap, B. B., Flicker, L., & Martin, S. A. (2021). Testosterone, cognitive decline, and dementia in older men. The Journal of Clinical Endocrinology & Metabolism, 106(11), e4753-e4766. doi.org/10.1210/clinem/dgab483

Yildiz, O., Aykan, A. C., Cetin, M., Demirbag, R., & Senarslan, O. (2021). The association between endogenous testosterone levels and the severity of coronary artery disease in men. Coronary Artery Disease, 32(1), 60–66. doi.org/10.1097/MCA.0000000000000913